What booming biotech means for Greater Boston and beyond
Support the news
A biotech CEO argues that the biggest news in the sector is not the creation of cures for specific diseases but rather of whole new types of treatments.
The hope and promise of lifesaving medical treatments fuel biotech investor exuberance to the tune of billions of dollars per year in Massachusetts. MIT's Andrew Lo breaks down how a...
The biotech industry needs to invest more in developing therapies for childhood diseases, ideally ones that can be given before symptoms arise, writes Geoff McDonough.
Two leaders in biotech -- both women -- discuss how women in management benefit biotech companies, and what's being done to bring more women into executive office suites and board...
Noubar Afeyan is one of biotech's most prolific investors.
We speak with Cambridge residents about how the biotech explosion is affecting the city, from swelling rents to -- arguably -- the further corporatization of Harvard Square.
Investors think Moderna Therapeutics holds a lot of promise -- a new technology that could revolutionize thousands of medicines.
It's time for the life sciences industry to expand access and opportunity to more women, people of color and people at all socioeconomic levels, writes David Lucchino, the chairman of...
We look at the history of the biotech industry in Boston.
The state Legislature is expected to pass a measure that would invest another $500 million in life science over the next five years.